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Abstract
The amygdala is innervated by the cholinergic system and is involved in major depressive disorder 
(MDD). Evidence suggests a hyper-activate cholinergic system in MDD. Hippocampal 
Cholinergic Neurostimulating Peptide (HCNP) regulates acetylcholine synthesis. The aim of the 
present work was to investigate expression levels of HCNP-precursor protein (HCNP-pp) mRNA 
and other cholinergic-related genes in the postmortem amygdala of MDD patients and matched 
controls (females: N=16 pairs; males: N=12 pairs), and in the mouse unpredictable chronic mild 
stress (UCMS) model that induced elevated anxiety-/depressive-like behaviors (females: N=6 
pairs; males: N=6 pairs). Results indicate an up-regulation of HCNP-pp mRNA in the amygdala of 
women with MDD (p<0.0001), but not males, and of UCMS-exposed mice (males and females; 
p=0.037). HCNP-pp protein levels were investigated in the human female cohort, but no 
difference was found. There were no differences in gene expression of acetylcholinesterase 
(AChE), muscarinic (mAChRs) or nicotinic receptors (nAChRs) between MDD subjects and 
controls or UCMS and control mice, except for an up-regulation of AChE in UCMS-exposed mice 
(males and females; p=0.044). Exploratory analyses revealed a baseline expression difference of 
cholinergic signaling-related genes between women and men (p<0.0001). In conclusion, elevated 
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amygdala HCNP-pp expression may contribute to mechanisms of MDD in women, potentially 
independently from regulating the cholinergic system. The differential expression of genes 
between women and men could also contribute to the increased vulnerability of females to 
develop MDD.
Keywords
Hippocampal Cholinergic Neurostimulating Peptide; depression; cholinergic system; postmortem; 
amygdala; mRNA gene expression
Introduction
Major Depressive Disorder (MDD) is a severe mental disorder that is often chronic and 
recurrent and that leads to substantial impairments in an individual’s ability to take care of 
everyday responsibilities. MDD is the leading cause of disability worldwide, as measured by 
years lost due to disability (WHO, 2008). The World Health Organization ranked MDD as 
the 3rd leading cause of burden of disease as of 2004, but importantly, projected that MDD 
would be the number one cause for burden of disease by 2030 (WHO, 2008).
In the 1970s, Janowsky et al. first proposed a possible involvement of the cholinergic system 
in the etiology of MDD (Janowsky et al., 1974; Janowsky et al., 1972). They hypothesized 
that a given affective state may represent a balance between central cholinergic and 
adrenergic neurotransmitter activity in those areas of the brain that regulate affect, with 
depression being a disease of cholinergic dominance and mania being a disease of 
adrenergic dominance (Janowsky et al., 1974; Janowsky et al., 1972). This possible 
mechanism was recently revisited by Mineur and Piccioto (Mineur and Picciotto, 2010). 
Neurotransmission of the cholinergic system is carried out by acetylcholine (ACh), which is 
synthesized by cholineacetyltransferase (ChAt) and degraded by acetylcholinesterase 
(AChE). The main receptors for ACh are the nicotinic (nAChRs) and muscarinic (mAChRs) 
receptors. Several lines of evidence suggest involvement of the cholinergic system in MDD. 
Organophosphate poisoning inhibits AChE, resulting in increased ACh, and can cause 
depressive-like behavior in humans (Gershon and Shaw, 1961). Additionally, a neural 
nAChR antagonist reduces anxiety-like behavior in mice (Roni and Rahman, 2011) and an 
α4β2nAChR partial agonist elicits antidepressant properties in the forced swim test in mice 
(Zhang et al., 2012). Administration of scopolamine (a mAChR antagonist) showed 
antidepressant properties in unipolar and bipolar patients (Drevets and Furey, 2010; Furey 
and Drevets, 2006; Furey et al., 2010), and MDD patients on both oral scopolamine and 
citalopram had better remission rates than with citalopram alone (Khajavi et al., 2012). 
Many MDD patients exhibit sleep disturbances, including a decrease in rapid eye movement 
(REM) latency. Interestingly, a cholinergic agonist produced a faster induction of REM 
sleep only in MDD patients and in subjects at high risk for psychiatric disorders (Palagini et 
al., 2013). Finally, knockdown of AChE in the hippocampus of adult mice increases anxiety- 
and depression-like behaviors and susceptibility to social stress, which was prevented by 
fluoxetine (Mineur et al., 2013). Taken together, these results support the idea that hyper-
activation of the cholinergic system may be involved in MDD.
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Hippocampal Cholinergic Neurostimulating Peptide (HCNP) is involved in regulating ACh 
synthesis in a medial septal nucleus culture system (Ojika et al., 1992) by increasing the 
levels of ChAT in cholinergic neurons (Uematsu et al., 2009). HCNP is an undecapeptide 
cleaved from the precursor protein (HCNP-pp) (Otsuka and Ojika, 1996). HCNP-pp is also 
known as phosphatidylethanolamine-binding protein (PEBP) and Raf kinase inhibitor 
protein (RKIP) (Sedivy, 2011). The release of HCNP from hippocampal culture is 
specifically mediated by the NMDAR (Ojika et al., 1998). Results suggest that HCNP/
HCNP-pp also acts as a key regulator for differentiation of cultured hippocampal progenitor 
cells (Sagisaka et al., 2010).
At the neural network level, changes in the function of several cortical and subcortical brain 
regions are thought to underlie the mood regulation deficit in depression (Seminowicz et al., 
2004). We previously found differential gene expression in the amygdala of men and 
women with MDD compared to controls, although with notable sex differences (Guilloux et 
al., 2012; Sibille et al., 2009). This is in accordance with neuroimaging studies showing 
reduced volume or grey matter density of the amygdala in female MDD patients compared 
to control subjects, with no change in male MDD (Hastings et al., 2004; Kong et al., 2013).
The amygdala receives cholinergic input from the Nucleus Basalis of Meynert (Schafer et 
al., 1998) and expresses both muscarinic and nicotinic receptors (Klein and Yakel, 2006; 
McDonald and Mascagni, 2010; 2011). However, the cholinergic system in the amygdala 
has not been studied in detail in MDD subjects. Here, our working hypothesis is that HCNP-
pp expression in the amygdala is involved in the pathogenesis of MDD by regulating the 
cholinergic system through HCNP. The aim of the present work was to investigate gene 
expression levels of HCNP-pp and genes involved in the cholinergic system in the 
postmortem amygdala of MDD patients and matched controls, and in a mouse model that 
elicits increased anxiety-/depressive-like behaviors.
Materials and Methods
Details of all methods are available in the Supplementary Information.
Human postmortem subjects
Brain samples were obtained after consent from next-of-kin during autopsies conducted at 
the Allegheny County Medical Examiner’s Office (Pittsburgh, PA, USA) using procedures 
approved by University of Pittsburgh’s Institutional Review Board and Committee for 
Oversight of Research Involving the Dead. Two cohorts of MDD subjects were examined 
here (male, n=12 pairs; female, n=16 pairs). Each MDD subject was matched with one 
control subject for sex and as closely as possible for age (Tables 1 and 2). See cohort details 
in Supplementary Information and (Guilloux et al., 2012; Sibille et al., 2009). The effects of 
putative confounds (age, antidepressants, death by suicide, pH, PMI, RNA ratio, RIN) were 
evaluated. When comparing male MDD subjects versus male controls, or female MDD 
subjects versus female controls, subject groups did not differ in mean age, postmortem 
interval (PMI), RNA integrity number (RIN), RNA ratio, or brain pH, as determined by one-
way ANOVA (p>0.05). When comparing men and women, pH and RNA ratio were 
significantly different (p=0.009 and p=0.004, respectively) in MDD patients but they did not 
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differ in RIN. Importantly, RIN is a better indicator of RNA quality than pH (Stan et al., 
2006) or RNA ratio (Copois et al., 2007). Subjects did not differ in mean age, 
antidepressants, death by suicide or PMI. Male and female control subjects did not differ by 
age, pH, PMI, RNA ratio, or RIN. Significant co-factors were included in the ANCOVA 
analyses.
Protein purification and Western blotting
Following RNA extraction using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), acetone 
precipitation of proteins was carried out (Guilloux et al., 2012). Using Western blotting, 
HCNP-pp signal ratios relative to actin were calculated. To reduce the within- and between-
subject measurement variance, samples were processed in matched pairs on the same gel 
four times, and results were replicated for a total of four different Western blots, with 16 
replicates per pair (Curley et al., 2011).
Mouse samples
Amygdala cDNA from a mouse cohort previously described was used (Edgar et al., 2011).
Real-time quantitative polymerase chain reaction (qPCR)
qPCR analyses were performed using specific primers for HCNP-pp, AChE, ChAt, 
mAChRs (1-4) and nAChRs (α3, α4, α7, and β2) and three internal controls (beta-actin, 
cyclophilin A, glyceraldehyde-3-phosphate dehydrogenase) on amygdala cDNA samples, as 
described previously (Sibille et al., 2009). In brief, small PCR products (80–120 basepairs) 
were amplified in quadruplet on an Opticon real-time PCR machine (BioRad, Waltham, 
MA, USA). Each qPCR run included one MDD subject and one matched control.
Using a similar qPCR methodology as described above for human samples, qPCR on mouse 
samples was performed. Each run included one UCMS mouse and one control mouse, 
matched for sex.
Statistical analysis
Human samples—Diagnosis-related expression differences in gene of interest (GOI) 
signal were determined by analysis of covariance (ANCOVA) using SPSS (SPSS, Inc., 
Chicago, IL, USA). Relevant factors showing significant differences by ANOVA were 
included in the ANCOVA model. The qPCR data were averaged across the four replicates 
and transformed into expression levels relative to the internal control genes. Variance 
homogeneity was tested by Levenés test. Sex-related expression differences in GOI signal 
were determined by analysis of covariance (ANCOVA), using a similar method. Since gene 
expression in sex-related comparisons did not present variance homogeneity, data were 
transformed by taking the logarithm (ln) of gene expression values.
Mouse samples—Statistical analysis was performed using SPSS. The qPCR data were 
averaged across the four replicates and transformed into expression levels relative to the 
internal control genes. Sex was tested as the main factor in a one-way ANOVA. UCMS and 
control groups were compared in the ANOVA model with GOI mRNA as the dependent 
variable and subject group as the main effect.
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Both in human and mouse samples, correlation between genes expression was tested by 
Pearson correlation. p<0.05 was considered statistically significant.
Western blot statistical analysis—A diagnosis-related expression difference in protein 
relative expression was determined by ANCOVA. The Western blot data were averaged 
across the sixteen replicates for each subject. Variance homogeneity was tested by Levenés 
test. To determine relevant covariates, the same approach as for gene expression was used. 
Covariate factors with significant effects were used in the ANCOVA model with relative 
protein level as the dependent variable and subject group as the main effect.
Results
HCNP-pp mRNA expression is up-regulated in the amygdala of women with MDD
We investigated mRNA expression of HCNP-pp in postmortem brains of men and women 
with MDD and in matched control subjects. For scale cofactors (age, pH, RNA ratio, RIN, 
PMI) and nominal cofactors (sex, tobacco, antidepressants, suicide, and cohort), pH, sex and 
cohort were significant after Bonferroni-Holm correction and included in the ANCOVA 
model. We observed a significant increase in HCNP-pp mRNA expression in the combined 
male/female MDD subject group compared with controls (F=21.794, p<0.0001) (Figure 1a). 
In view of previously-reported sex differences in MDD-related gene changes in the 
amygdala and since women are twice as likely to have MDD compared to men (Kessler et 
al., 2003), we explored the potential contribution of sex to differential HCNP-pp expression 
in MDD. No scale or nominal cofactors were significant in females. HCNP-pp was 
significantly increased in the amygdala of women with MDD compared to controls 
(F=51.316, p<0.0001; Fig 1b). In males, no significant difference was observed in HCNP-pp 
expression between MDD subjects and controls (age as cofactor; Fig 1c).
Unchanged HCNP-pp protein level in female amygdala
We next investigated whether the up-regulation of HCNP-pp mRNA in the amygdala of 
females with MDD was associated with protein changes. Using a Western blot approach in 
postmortem female amygdala (N=15 pairs), we found no change in HCNP-pp between 
MDD and controls (F=0.525, p=0.475; cofactors: age and PMI) and no correlation with 
mRNA expression (Pearson R=0.127, p=0.503).
Absence of expression changes for cholinergic-related genes in the amygdala of MDD 
subjects
Since HNCP-pp/HCNP affects the production of ACh, we next investigated expression of 
genes related to the cholinergic system in the same postmortem amygdala samples, 
including mAChRs (1-4), nAChRs (α3, α4, α7, β2), ChAt, and AChE. The expression levels 
of ChAt and β2nAChR were too low in these samples, and were thus excluded from further 
analyses. We found no difference in the expression of these genes between MDD subjects 
and controls (Figure 2) (cofactors in the ANCOVA model: RNA ratio for AChE, nAChRs 
α3, α7; age and pH for nAChRs α3, α7). Interestingly, we found a robust main effect of sex 
on gene expression. Specifically, control females had significantly higher expression levels 
in compared to control males for AChE, mAChRs (1, 2 and 4), and nAChRs α3, α4 and α7 
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(cofactors: RNA ratio for nAChRα7; p<0.0001 for all genes examined), except for m3 
which showed no differences between control males and females (Figure 3a). This 
differential expression was also present in MDD subjects. Specifically, AChE (cofactors: 
RNA ratio), mAChRs (1, 2 and 4, cofactors: pH, RNA ratio) and nAChRs (α3 and α7, 
cofactors: pH, RNA ratio; α4, cofactors: RNA ratio), showed significantly higher expression 
levels in female MDD subjects compared to male MDD subjects (p<0.0001 for all genes 
examined), except for m3 which showed no differences between MDD males and females 
(Figure 3b). This differential expression between females and males was also observed when 
analyzing controls and patients together (p<0.0001; data not shown). Cholinergic-related 
genes were not affected by antidepressant treatment in MDD patients.
HCNP-pp mRNA expression is up-regulated in the amygdala of mice exposed to chronic 
stress
We examined gene expression of HCNP-pp in the amygdala of mice exposed to UCMS and 
non-stressed controls using samples from a previous study (Edgar et al., 2011). In that study, 
mice exposed to UCMS for a period of 4 weeks responded with characteristic increases in 
anxiety-/depressive-like behavior. Analyzing the females and males together (N=12 pairs), 
we found an up-regulation of HCNP-pp in the amygdala of UCMS mice compared to 
controls (F=4.912, p=0.037) (Figure 4a). Separated by sex, both groups showed a similar but 
non-significant increase in HCNP-pp expression (Figure 4b).
AChE expression is up-regulated in the amygdala of UCMS-exposed mice
We examined expression of mAChRs (1-4), nAChRs (α3, α4, α7, β2), ChAt, and AChE in 
the amygdala of mice exposed to chronic stress. The expression levels of ChAt, α4nAChR, 
and β2nAChR were too low, and were thus excluded from further analyses. Analyzing the 
females and males together, we observed an increased expression of AChE in the amygdala 
of UCMS-exposed mice compared to controls (F=4.559, p=0.044) (Figure 5). No difference 
in expression of mAChRs or nAChRs expression was found.
We also performed a differential expression analysis in the combined male/female cohort, as 
performed in the human experiments. No sex differences in gene expression were observed 
(data not shown).
Gene expression correlation patterns in postmortem amygdala
Given that all cholinergic pathway genes are essential for efficient cholinergic 
neurotransmission, it is likely that they are expressed in a coordinated fashion. It is thus 
possible that this co-expression structure may vary in MDD. Therefore, we investigated the 
degree of relationship between HCNP-pp and cholinergic-related genes expression in the 
human and mouse samples (Tables 3 and 4, respectively). In humans, we found significant 
correlations between several cholinergic genes expression both in control and MDD, in both 
sexes (Table 3). However, the correlation between HCNP-pp and cholinergic-related genes 
was observed only in men. Specifically, HCNP-pp expression was correlated with AChE 
and m2 in control and MDD subjects, with m1 and 4 expression in control male subjects and 
with m3 and nα4 in male MDD subjects. In the mouse amygdala, HCNP-pp expression was 
correlated with AChE in male and female mice exposed to UCMS and female controls. 
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HCNP-pp expression was also correlated with m1, 2, 4 and nα7 in female UCMS-exposed 
mice and with m1 in female controls (Table 4).
Discussion
In the present study, we report an up-regulation of HCNP-pp mRNA in the postmortem 
amygdala of women with MDD, with no change in men with MDD. Moreover, we found an 
up-regulation of genes involved in the cholinergic system in women compared to men, but 
no changes between MDD and control subjects. Also, we report a less robust up-regulation 
of HCNP-pp mRNA expression and an up-regulation of AChE in the amygdala of mice 
exposed to UCMS compared to controls. As in humans, no change was observed in genes 
related to the cholinergic system (except for AChE) between UCMS and control mice. 
Finally, we report a correlation in the expression of genes related to the cholinergic system 
in both humans and mice, as expected for an integrated neurotransmitter system. Together, 
the present results suggest that the differential expression of HCNP-pp observed in female 
MDD is not correlated with changes in the cholinergic system, at least at the mRNA level 
and in the amygdala. On the other hand, sex differences in expression of components of the 
cholinergic system might play a role in the increased susceptibility of women to suffer 
MDD.
HCNP-pp expression in human postmortem amygdala
The up-regulation of HCNP-pp is in accordance with results showing that an over-
expression of HCNP/HCNP-pp in the hippocampus from early life in transgenic mice elicits 
a depressive-like phenotype in old age (Matsukawa et al., 2010). Also, a reduction of 
HCNP-pp mRNA was found in the postmortem hippocampus of late Alzheimeŕs disease 
(AD) patients compared to controls (Maki et al., 2002), but these findings may be related to 
the overall AD-related reduction in cholinergic neurotransmission (Gil-Bea et al., 2005), 
rather than to MDD-related mechanisms where a hyper-activation of this system has been 
proposed.
Despite the observed up-regulation of HCNP-pp in amygdala of women with MDD, we 
found no changes in protein expression or correlation with mRNA levels, although 
limitations in detection method may have yielded false negative results (See limitations). 
This was surprising, although in agreement with previous reports indicating no correlation 
between HCNP-pp mRNA and protein levels (Tohdoh et al., 1997). Another study by 
Greenbaum et al. (2003) suggested three reasons for poor correlations between mRNA and 
protein levels: complicated and varied post-transcriptional mechanisms, protein in vivo half-
lives, and/or error and noise in both protein and mRNA experiments (Greenbaum et al., 
2003).
HCNP-pp regulation of the cholinergic system in the human amygdala
We found no difference in mRNA expression of AChE, nAChRs, or mAChRs between 
MDD subjects and matched controls when men and women were analyzed together or 
separately. Previous studies showed no change of β2nAChRs availability in the amygdala or 
hippocampus in MDD patients (Saricicek et al., 2012). Also, no difference in α7nAChRs 
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was found between postmortem hippocampus or perirhinal cortex of MDD patients and 
controls (Thomsen et al., 2011). On the other hand, no association between polymorphisms 
in m2AChR and MDD was found (Cohen-Woods et al., 2009), although there is opposing 
evidence (Comings et al., 2002; Wang et al., 2004). These results suggest that the 
differential expression of HCNP-pp does not affect expression of genes related to the 
cholinergic system in the amygdala. Interestingly, we found a strong correlation between the 
expression of HCNP-pp and AChE and ACh receptors in men (both MDD and control), but 
not in women. Thus, if HCNP-pp increases ACh levels with no increase in AChE or change 
in the receptors, high levels of ACh in the female brain could increase MDD vulnerability. 
On the other hand, when analyzing only the cholinergic-related genes, some correlations are 
present in control but not in MDD and vice versa, both in men and women, indicating that 
some degree of deregulation is present in the cholinergic system in the amygdala of MDD 
patients.
Sex difference of cholinergic genes expression in the amygdala
Interestingly, we found a robust up-regulation of genes related to the cholinergic system in 
women compared to men. We have previously reported differential expression of other 
genes, related to mitochondrial function for instance, in the amygdala between men and 
women (Lin et al., 2011), which together suggest that structural differences in amygdala 
gene expression may contribute to the increased susceptibility of women to suffer from 
MDD compared to men, and may include a cholinergic component. Indeed, sex differences 
in cholinergic function were observed, whereas women respond in a greater proportion and 
magnitude than men to scopolamine treatment for MDD and BD (Furey et al., 2010). Also, 
female non-smokers have higher availability of β2nAChR in certain brain regions compared 
to male non-smokers (Cosgrove et al., 2012). Moreover, women respond differently to 
administration of physostigmine (a reversible cholinesterase inhibitor that elevates ACh 
levels in the brain) (Rubin et al., 2003; Rubin et al., 1999).
Although the underlying mechanism that explains gender differences remains unclear, there 
are indications that hormones may have an important role in modulating the cholinergic 
system. In this sense, primary cultures of rat basal forebrain neurons exposed to 
physiological concentration of estrogen increased newly synthesized ACh (Pongrac et al., 
2004). Also, chronic estradiol replacement significantly enhanced potassium-stimulated 
acetylcholine release in the hippocampus of ovariectomized rats (Gibbs et al., 2004).
Here, we did not observe differential expression of cholinergic-related genes between male 
and female mice, suggesting these differences may not be conserved across species, 
although additional studies are warranted. Studies comparing the expression of cholinergic-
related genes in both the central nervous system and periphery in male and female mice are 
scarce. One study showed increased expression of all mAChRs(1–5) in the frontal cortex in 
males and of mAChRs 1–4 in the striatum in females, with no difference in other brain 
regions (including the hippocampus) (Benes et al., 2013). Another study showed differential 
activity of ChAT between males and females in the hippocampus at 17- and 25-months old 
but not at 5-months (Frick et al., 2002).
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HCNP-pp expression in mouse amygdala
Consistent with the results in MDD subjects, we found an up-regulation of HCNP-pp 
mRNA expression in the amygdala of mice exposed to UCMS compared to controls, 
although no sex difference was found. Despite the finding that transgenic mice which over-
express HCNP-pp exhibit depressive-like behaviors in old age (Matsukawa et al., 2010), 
another study reported a reduction of HCNP-pp in the hippocampus of rats exposed to stress 
(Kim and Kim, 2007). The latter result is in opposition with our observations, which may be 
explained by differences in methodology and/or brain region studied, namely different stress 
protocol, outcome measures, and region investigated.
HCNP-pp regulation of the cholinergic system in the mouse amygdala
As in the human cohorts, we did not find differential expression of genes related to the 
cholinergic system between UCMS-exposed and control mice, except for an up-regulation 
of AChE in UCMS-exposed mice. The up-regulation of AChE expression in the amygdala 
of UCMS-exposed mice may be a compensatory effect of increased ACh triggered by 
HCNP-pp, although further studies are needed to confirm this hypothesis. Also, we found a 
correlation between HCNP-pp and acetylcholine receptors expression only in females, 
especially in UCMS-exposed mice, suggesting sex-related differences in mechanisms 
involved in anxiety-/depressive-like behaviors between humans and mice for the cholinergic 
system.
Limitations
Some of the limitations of this study are inherent to investigation of heterogeneous cohorts 
and postmortem brain samples. Large numbers of clinical, demographic, and technical 
parameters have to be taken into consideration, and results are mostly correlative and cannot 
provide insight into developmental processes in MDD. The effects of putative confounds 
(antidepressants, death by suicide, pH, PMI, RNA ratio, RIN) were evaluated, however 
small samples sizes in parameter-delineated subgroups may have precluded definitive 
interpretations regarding the potential influence of these factors on the findings. For male 
MDD subjects, 4/12 had antidepressants present at the time of death and 6/12 died by 
suicide. For female MDD subjects, 11/16 had antidepressants present at the time of death 
and 6/16 died by suicide. No difference in HCNP-pp expression or in any other gene 
examined was found between patients who died by suicide compared to other modes of 
death or with or without AD (data not shown).
Other variables related to postmortem tissue samples (PMI, pH RNA ratio, RIN) were 
analyzed. pH of all brains used in this study was ≥6.1, a suggested value in the context of 
sudden deaths (Lewis, 2002). For RNA ratio, there was no correlation with RIN, which is a 
better indicator of RNA degradation (Copois et al., 2007). When comparing men and 
women, pH and RNA ratio were significantly different (p=0.009 and p=0.004, respectively) 
in MDD patients. Specifically, pH was considered as a cofactor for mAChRs 1, 2 and 4, and 
nAChRs α3 and α7. RNA ratio was considered as a cofactor for AChE, mAChRs 1, 2 and 4, 
and nAChRs α3, α7, and α4. Since pH and RNA ratio were not different between control 
males and females, it is unlikely that the results in MDD subjects were confounded by these 
parameters. Also RIN values did not differ between MDD females and males, which, as 
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mentioned earlier, is a better indicator of RNA quality than pH (Stan et al., 2006) or RNA 
ratio (Copois et al., 2007), supporting the significance of the overall findings.
HCNP-pp protein levels were significantly positively correlated with PMI. With one 
exception, all samples had PMI less than 30 hours, which is acceptable for human studies 
(Atz et al., 2007). Also, no difference in PMI was found between MDD and control subjects. 
Moreover, since there is a positive correlation between protein expression and PMI, it does 
not seem that the protein stability would be affected by this variable.
We measured HCNP-pp protein levels instead of HCNP since there is no commercially 
available antibody for the latter. Finally, we did not measure ChAt protein levels in the 
amygdala and only evaluated the cholinergic system in an indirect way by measuring the 
levels of gene transcript of mAChRs, nAChRs, and AChE.
Summary
In summary, we found an up-regulation of HCNP-pp mRNA in the postmortem amygdala of 
women with MDD but no change at the protein level. Since HCNP-pp is a precursor protein, 
changes in processing and post-translational modifications occur and may not have been 
measured here. Two alternate hypotheses/mechanisms are possible: First, even though we 
did not find a differential expression of acetylcholine receptors in the amygdala between 
MDD and control subjects, we cannot rule out a cholinergic deregulation in this structure 
(since different mechanisms can regulate receptor expression or function). In support, 
chronic administration of nicotine produced an up-regulation of β2α4nAChRs with no 
change at the mRNA level (Corringer et al., 2006). The amygdala receives cholinergic input 
from the Nucleus Basalis of Meynert located in the basal forebrain. ChAt is synthetized in 
the cytoplasm of the cholinergic neuron and is transported through the axon to the nerve 
terminals where it synthesizes Ach (Oda, 1999). At the same time, the amygdalar complex 
projects to the basal forebrain, in particular to the cholinergic neurons of the ventrolateral 
substantia innominata (Jolkkonen et al., 2002). Thus, it is possible that HCNP-pp, in 
particular HCNP, exerts its action in a different brain region since ChAt mRNA levels were 
too low in the amygdala in our cohort, and previous studies showed no detection of ChAt 
mRNA in the amygdala (Oda, 1999). A possible mechanism is that HCNP travels from the 
amygdala to the basal forebrain where it can regulate the expression of ChAt mRNA. This 
hypothesis is in accordance with previous experiments showing that an over-expression of 
HCNP-pp in the hippocampus increases the levels of ChAt in the septal nucleus (Uematsu et 
al., 2009), the main cholinergic projection to the hippocampus. However, further 
experiments are needed to test this hypothesis.
Although regulation the cholinergic system is the more plausible hypothesis for the function 
of HCNP-pp, considering that a correlation between HCNP-pp and cholinergic-related genes 
is observed in men, an alternate hypothesis is that the differential expression of HCNP-pp 
mRNA is affecting the cellular population in the amygdala. In addition to its role in 
regulating the cholinergic system, HCNP/HCNP-pp is also involved in differentiation of 
cultured adult rat hippocampal progenitor cells. More specifically, a down-regulation of 
HCNP-pp was correlated with an up-regulation of GFAP (astrocyte marker) (Sagisaka et al., 
2010). There is evidence of decreased GFAP in the amygdala of MDD patients, possibly 
Bassi et al. Page 10
J Psychiatr Res. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
indicating a reduction of astrocyte density (Altshuler et al., 2010). Also, a reduction in glia 
was found in MDD patients (Bowley et al., 2002). Taking this in consideration, the up-
regulation of HCNP-pp we observed in the amygdala of women with MDD might be 
preventing progenitor cells from differentiating into astrocytes. Interestingly, reduced 
volume of the amygdala was reported in female MDD patients compared to control subjects, 
with no change in male MDD patients (Hastings et al., 2004). However, when analyzing the 
expression of GFAP in a previous study with the same samples used in our study, no 
difference between MDD and control postmortem female amygdala was found (Guilloux et 
al., 2012).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research highlights
• Hippocampal Cholinergic Neurostimulating Peptide (HCNP) is upregulated in 
depression
• HCNP-pp expression is upregulated in the amygdala of female but not men in 
depression
• HCNP-pp expression is upregulated in the amygdala of stressed mice
• Findings are independent of changes in cholinergic-related genes
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Figure 1. 
mRNA expression of HCNP-pp in postmortem amygdala of men and women with MDD 
assessed by qPCR. a. HCNP-pp mRNA expression between MDD and control subjects 
(F=21,794, p<0.0001), using pH as cofactor. b. HCNP-pp mRNA expression between 
female MDD and control subjects (F=51.316, p<0.0001). c. HCNP-pp mRNA expression 
between male MDD and control subjects (non-significant). Error bars represent standard 
error.
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Figure 2. 
mRNA expression of cholinergic signaling-related genes in postmortem amygdala of 
controls and MDD subjects assessed by qPCR. mAChRs (1-4), nAChRs (α3, α4, α7), or 
AChE mRNA expression between MDD and control subjects (non-significant). Error bars 
represent standard error.
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Figure 3. 
mRNA expression of cholinergic signaling-related genes in postmortem amygdala of men 
and women assessed by qPCR. a. mAChRs (1, 2, 4), nAChRs (α3, α4, α7), or AChE mRNA 
expression between men and women in the control subjects (**, p<0.0001). b. mAChRs (1, 
2, 4), nAChRs (α3, α4, α7), or AChE mRNA expression between men and women in the 
MDD subjects (**, p<0.0001). Error bars represent standard error.
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Figure 4. 
mRNA expression of HCNP-pp in amygdala of mice exposed to UCMS and non-stressed 
controls assessed by qPCR. a. HCNP-pp mRNA expression between UCMS and control 
subjects (F=4.912, p=0.037). b. HCNP-pp mRNA expression between female and males 
UCMS and matched control subjects (n.s. = non-significant). Error bars represent standard 
error.
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Figure 5. 
mRNA expression of AChE in amygdala of mice exposed to UCMS and non-stressed 
controls assessed by qPCR. AChE mRNA expression between UCMS and control subjects 
(F=4.559, p=0.044). Error bars represent standard error.
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